SCHEMBL6674932

SCHEMBL6674932

O=C(O)c1ccc(COc2cc(OCc3ccc(C(=O)O)cc3)cc(C(=O)Nc3ccc(/C=C/c4ccccc4)cc3C(=O)O)c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 2/20 0.53
KMT2A Q03164 5/20 0.50
MEN1 O00255 4/20 0.50
LTC4S Q16873 1/20 0.48
CTDSP1 Q9GZU7 2/20 0.46
APOBEC3A P31941 1/20 0.46
APOBEC3G Q9HC16 1/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
RXFP1 Q9HBX9 1/20 0.46
HDAC1 Q13547 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
NR4A1 P22736 1/20 0.45
NR4A2 P43354 1/20 0.45
NR4A3 Q92570 1/20 0.45
NR1H4 Q96RI1 2/20 0.45
CYSLTR2 Q9NS75 1/20 0.45
CYSLTR1 Q9Y271 1/20 0.45
CASP3 P42574 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6674936 1.00 GCK (0.53) GCKKMT2AMEN1LTC4SCTDSP1
SCHEMBL6678428 0.90 NR1H4 (0.51) GCKKMT2AMEN1LTC4SHDAC1
SCHEMBL6678422 0.90 NR1H4 (0.51) GCKKMT2AMEN1LTC4SHDAC1
SCHEMBL6674560 0.86 LTC4S (0.45) KMT2AMEN1LTC4SNPC1RAB9A
SCHEMBL6674556 0.86 LTC4S (0.45) KMT2AMEN1LTC4SNPC1RAB9A
SCHEMBL6677957 0.82 KDM4E (0.58) KMT2AMEN1NPC1RAB9ACASP3
SCHEMBL6677951 0.82 KDM4E (0.58) KMT2AMEN1NPC1RAB9ACASP3
SCHEMBL6674346 0.79 MEN1 (0.62) KMT2AMEN1LTC4SHDAC1PKM
SCHEMBL6673496 0.79 MEN1 (0.62) KMT2AMEN1LTC4SHDAC1PKM
SCHEMBL6675963 0.78 PTPN1 (0.56) KMT2AMEN1LTC4SPKMTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020032218-A1 Substituted stilbenes as glucose uptake enhancers TELIK, INC. 2002-03-14 US claimed
EP-1289936-B1 SUBSTITUTED STILBENES AS GLUCOSE UPTAKE ENHANCERS TELIK INC (US) 2004-10-20 EP disclosed
US-6479548-B2 P-(BENZOYLAMINO)STILBENE DERIVATIVES TELIK, INC. 2002-11-12 US disclosed
US-20020032218-A1 Substituted stilbenes as glucose uptake enhancers TELIK, INC. 2002-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020032218-A1 Substituted stilbenes as glucose uptake enhancers SLC2A1, SLC2A8, SLC2A2 GCK 14/4885KMT2A 3788/4885MEN1 2354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.